source
- Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemiaAlethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…
- Alethio Therapeutics secures $90 million to develop treatments for rare blood cancersAlethio Therapeutics, a UK based biotechnology startup, announced it has raised $90 million in new financing. The capital will be used to advance its pipeline targeting myeloproliferative neoplasm…